The Prognosis Of Hyerthermic Intraperitoneal Chemotherapy For Recurrent Ovarian Cancer:a Meta-analysis

Objective:To evaluate prognosis of patients with recurrent ovarian cancer(ROC)treated with hyperthermic intraperitoneal cemotherapy(HIPEC).Methods:Datebase such as We searche PubMed,EMbase,The Cochrane Library,Web of Science,CNKI,VIP and WanFang Data were retrieved by computer.All study on HIPEC in the treatment of recurrent ovarian cancer was collected.Study was selected according to the established inclusion and exclusion criteria.The hazard ratio(HR)and 95%confidence interval(95%CI)were used as the effect indicators.The Stata12.0 sofware was used to conduct meta-analysis.Results:A total of 11 studies involving 691 were included.in 9 of the studies with 581 were describe the overall survival of HIPEC in the treatment of recurrent ovarian cancer,the results of Meta-analysis showed that the HIPEC can improve overall survival in patients with recurrent ovarian cancer[HR = 0.55,95%CI(0.39,0.77),P = 0.001].in 5 of the studies with 292 were describe the overall survival of HIPEC in thetreatment of platinum-sensitive recurrent ovarian cancer,the results of meta-analysis showed that the HIPEC can't improve Overall Survival in the platinum-sensitive recurrent ovarian cancer patients[HR = 0.61,95%CI(0.34,1.09),P=0.095];in 4 of the studies with 251 ROC people described the progression-free survival,the results of meta-analysis showed that the HIPEC can improve progression-free survival[HR = 0.48,95%CI(0.35,0.67),P = 0.000] and in 3 of the studies with 140 platinum-sensitive ROC described the progression-free survival,the results of meta-analysis showed that the HIPEC can improve platinum-sensitive ROC progression-free survival[HR = 0.49,95%CI(0.32,0.76),P = 0.001].Conclusion:Treatment with HIPEC can improve the prognosis of patients with recurrent ovairan cancer,but HIPEC can't improve the prognosis of patients with platinum-sensitive recurrent ovairan cancer.